Baird analyst Robert Mason lowered the firm’s price target on Novanta (NOVT) to $169 from $175 and keeps a Neutral rating on the shares. The firm said discrete customer decisions to defer ramps on new product intros, combined with capital goods demand softnes at year-end 2024 all contributing to revisions.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NOVT: